Telo Genomics Corp (TSE:TELO) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Telo Genomics Corp has achieved a significant milestone by obtaining a CLIA certification, enabling the company to commercialize its TeloView diagnostic tests for oncology in the USA and internationally. This designation will bolster its partnerships within the diagnostic industry, especially in the area of multiple myeloma where its TeloView tests can play a crucial role.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue